dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Antonuzzo, Lorenzo |
dc.contributor.author | Bachet, Jean-Baptiste |
dc.contributor.author | Kuan, Feng-Che |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Loupakis, Fotios |
dc.contributor.author | Pietrantonio, Filippo |
dc.date.accessioned | 2021-11-10T11:04:37Z |
dc.date.available | 2021-11-10T11:04:37Z |
dc.date.issued | 2020-10-31 |
dc.identifier.citation | Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, et al. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol. 2020 Oct 31;12:1–12. |
dc.identifier.issn | 1758-8359 |
dc.identifier.uri | https://hdl.handle.net/11351/6519 |
dc.description | Esdeveniments adversos; Càncer colorectal metastàtic; Regorafenib |
dc.description.sponsorship | The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Bayer. |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation.ispartofseries | Therapeutic Advances in Medical Oncology;12 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Recte - Càncer - Tractament |
dc.subject | Proteïnes quinases - Inhibidors - Ús terapèutic |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | Protein-Tyrosine Kinases |
dc.subject.mesh | /antagonists & inhibitors |
dc.subject.mesh | Clinical Decision-Making |
dc.title | Practical considerations in the use of regorafenib in metastatic colorectal cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1177/1758835920956862 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | proteína-tirosina cinasas |
dc.subject.decs | /antagonistas & inhibidores |
dc.subject.decs | toma de decisiones clínicas |
dc.relation.publishversion | https://doi.org/10.1177/1758835920956862 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Loupakis F] Unit of Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy. [Antonuzzo L] Medical Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. [Bachet JB] Sorbonne Université, Service d’hépato-gastroentérologie, Hôpital Pitié Salpêtrière – Paris 6, APHP, Paris, France. [Kuan FC] Department of Hematology and Oncology, Chang-Gung Memorial Hospital, Chiayi, Taiwan. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pietrantonio F] Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy |
dc.identifier.pmid | 33193826 |
dc.identifier.wos | 000587954500001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |